Metro-Minnesota Community Clinical Oncology Program

描述(由申请人提供)：大都会-明尼苏达社区临床肿瘤学(MMCCOP)项目具有悠久的历史，这清楚地证明了财团的成功，从最初财团成员的持续承诺和从1979年到2009年财团的增长都证明了这一点。MMCCOP联盟代表着一个建立起来的社区项目基础，该项目始于1979年，由NCI资助的社区医院癌症项目(CHCP)奖。这项计划将对社区提供癌症护理的方式产生重大影响，并为CCOP倡议提供基石。这个联合体在1983年申请并获得了NCI的社区临床肿瘤学计划(CCOP)赠款，并从1987年、1990年、1995年、2000年和2005年获得了随后的CCOP赠款。目前，MMCCOP联盟代表了12家医院和诊所，它们拥有共同的方法和建立的机制，以确定、登记和跟踪NCI赞助的治疗、癌症预防和癌症控制方案的参与者。MMCCOP社区的健康市场仍然竞争激烈，并因合并和明尼苏达州的医疗改革而不断变化。尽管环境不断变化，MMCCOP医院和相关工作人员仍在继续合作，支持临床研究试验中增加的时间和费用。在医院内的许多其他项目被减少或取消的时候，他们的支持水平并没有减少，实际上还增加了。该计划纳入了执业医师群体的相当一部分，并为过去25年来执业肿瘤学家、他们的医院管理部门和该联盟中的其他卫生专业人员之间的交流提供了基础。加在一起，联盟成员平均每年看到近12,000名新的分析性癌症患者。目前有110名调查人员，分别代表内科、放射科和外科肿瘤科，包括神经外科、胸外科和妇科肿瘤科，以及血液科、泌尿科、肿瘤科、神经科、耳鼻喉科、家庭实践和内科。MMCCOP研究基地从属关系的历史和积极主动地扩大获得NCI赞助研究的机会的方法支持了实现和保持CCOP倡议的NCI目标的能力。MMCCOP打算维持一个区域范围的社区联盟，向社区提供癌症预防、治疗和症状管理方面的最新进展。这将通过以下方式实现：继续与CTSU、ECOG、NCCTG、GOG、MD Anderson、NSABP、RTOG、URCC和CCCWFU建立联系；扩展现有的MMCCOP数据管理和通信系统，以增加研究人员参与权责发生、计划运作和研究基地活动的数量和水平；实施新战略，改善少数群体和未得到充分服务的群体的机会和参与；并提高专业和普通社区对CCOP和临床癌症试验好处的认识。此外，Metro-MN CCOP和MN CGOP研究计划的所有成员和附属机构都是由Park Nicollet研究所管理的社区肿瘤学计划机构审查委员会的成员。申请是在MMCCOP完成第26年赠款时提交的，这是自该联盟计划启动以来最成功的年份之一。在最近一次NCI资助的赠款期间(2009年5月6日)，NCI批准的治疗研究获得了242%的积分(235名患者)，批准的癌症控制方案获得了372.8个积分(396名新患者和370名参与者的随访)。MMCCCOP已经证明了每年有能力按照协议录入越来越多的患者，并提议在该奖项的第一年为治疗研究累计240个学分，为癌症控制提供350个学分，目标是继续超过NCI对这两种类型研究的要求。 相关性：明尼苏达州大都会社区临床肿瘤学计划(MMCCOP)是由国家癌症研究所(NCI)赞助的一项研究计划，旨在为我们社区的人们提供可用于癌症治疗、症状管理和癌症预防的最新疗法。自1983年成立以来，MMCCOP将社区癌症专家、初级保健医生和其他卫生保健专业人员联系到NCI支持的合作小组，进行NCI批准的治疗、化学预防、症状管理和生活质量临床试验(研究研究)。

DESCRIPTION (provided by applicant): The Metro-Minnesota Community Clinical Oncology (MMCCOP) program has a long-standing history which clearly demonstrates the success of the consortium as demonstrated by the both the ongoing commitment of the original consortium members and the growth of the consortium from 1979 through 2009. The MMCCOP consortium represents an established community program base which began in 1979 through its NCI-funded Community Hospital Cancer Program (CHCP) Award. This program would have a major impact on the way that cancer care is delivered in the community and provided the cornerstone for this CCOP initiative. This same consortium applied for and received the initial Community Clinical Oncology Program (CCOP) grant from the NCI in 1983, and has received subsequent CCOP grants since that time in 1987, 1990, 1995, and 2000 and 2005. Currently, the MMCCOP consortium represents twelve hospital and clinics with a common approach and established mechanisms for identifying, enrolling and following participants on NCI sponsored treatment, cancer prevention and cancer control protocols. The health market In the MMCCOP community remains extremely competitive and is in constant change as a result of mergers and Minnesota's healthcare reform. Despite this changing environment, the MMCCOP hospitals and associated staff continue to collaborate and support the added time and expense Involved In clinical research trials. Their level of support has not been cut back, and In fact has increased, during a time when many other projects within the hospitals are being reduced or eliminated. This program incorporates a substantial segment of the practicing physician community, and has provided a basis for communications between the practicing oncologists, their hospital administrations, and other health professionals in this consortium for the past twenty-five years. Combined, the consortium members see an average of nearly 12,000 new analytic cancer patients per year. Currently, there are 110 Investigators, representing medical, radiation and surgical oncology Including neuro-surgery, thoracic surgery and gynecologic oncology, and hematology, urology, oncology, neurology, ENT, family practice and Internal medicine. The history of MMCCOP Research Base Affiliations and proactive approach to expanding access to NCI sponsored studies supports the ability to achieve and maintain the NCI goals for the CCOP Initiative. MMCCOP intends to sustain a region wide community consortium which provides the community with the most recent advances in cancer prevention, treatment and symptom management. This will be accomplished through continued affiliations with CTSU, ECOG, NCCTG, GOG, MD Anderson, NSABP, RTOG, URCC and CCCWFU, the expansion of the current MMCCOP data management and communication system to increase the number and level of participation of the investigators In accrual, program operations and research base activities, implementation of new strategies to improve access and participation of minority and underserved groups, and increase the professional and lay community awareness of the CCOP and benefits of clinical cancer trials. In addition, all member and affiliate institutions of both Metro-MN CCOP and MN CGOP research programs are members of the Institutional Review Board for the Community Oncology Programs, administered by Park Nicollet Institute. The application is submitted as MMCCOP completes Grant Year 26 with one of most successful years since initiation of this consortium program. During the most recent NCI-Funded grant (6/05-5/09), 242 credits (235 patients) were accrued to NCI- approved treatment studies and 372.8 credits (396 new patients and follow-up of 370 participants) were accrued to approved cancer control protocols. MMCCCOP has demonstrated the ability to enter an increasing number of patients on protocol each year and proposes to accrue a total of 240 credits to Treatment studies and 350 Cancer Control credits in the first year of this award with the goal of continually exceeding the NCI requirements for both types of studies. RELEVANCE: The Metro Minnesota Community Clinical Oncology Program (MMCCOP) is a research program sponsored by the National Cancer Institute (NCI) to provide people in our community access to the newest therapy available for cancer treatment, symptom management and cancer prevention. Since Its inception in 1983, MMCCOP has linked community cancer specialists, primary care physicians and other health care professionals to the NCI-supported Cooperative Groups to conduct NCI-approved treatment, chemoprevention, symptom management and quality of life clinical trials (research studies).